CoChat
Sign Up
Cited by 329Neurogenesis and neuroplasticity mechanismsStroke Rehabilitation and RecoveryNerve injury and regeneration

The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.

Human neural stem cells enhance structural plasticity and axonal transport in the ischaemic brain

Open access
Andres, Robert H., Horie, Nobutaka, Slikker, William, Keren-Gill, Hadar, Zhan, Ke, Sun, Guohua, Manley, Nathan C., Pereira, Marta P., Sheikh, Lamiya A., McMillan, Erin L., Schaar, Bruce T., Svendsen, Clive N., Bliss, Tonya M., Steinberg, Gary K.·2011·Brain
DOI 10.1093/brain/awr094PMC PMC3102243
Open this paper in CoChat — free accountOpen PDF

Abstract

Stem cell transplantation promises new hope for the treatment of stroke although significant questions remain about how the grafted cells elicit their effects. One hypothesis is that transplanted stem cells enhance endogenous repair mechanisms activated after cerebral ischaemia. Recognizing that bilateral reorganization of surviving circuits is associated with recovery after stroke, we investigated the ability of transplanted human neural progenitor cells to enhance this structural plasticity. Our results show the first evidence that human neural progenitor cell treatment can significantly increase dendritic plasticity in both the ipsi- and contralesional cortex and this coincides with stem cell-induced functional recovery. Moreover, stem cell-grafted rats demonstrated increased corticocortical, corticostriatal, corticothalamic and corticospinal axonal rewiring from the contralesional side; with the transcallosal and corticospinal axonal sprouting correlating with functional recovery. Furthermore, we demonstrate that axonal transport, which is critical for both proper axonal function and axonal sprouting, is inhibited by stroke and that this is rescued by the stem cell treatment, thus identifying another novel potential mechanism of action of transplanted cells. Finally, we established in vitro co-culture assays in which these stem cells mimicked the effects observed in vivo. Through immunodepletion studies, we identified vascular endothelial growth factor, thrombospondins 1 and 2, and slit as mediators partially responsible for stem cell-induced effects on dendritic sprouting, axonal plasticity and axonal transport in vitro. Thus, we postulate that human neural progenitor cells aid recovery after stroke through secretion of factors that enhance brain repair and plasticity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/brain/awr094

Cites

71 of 71 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Differentiation fate of transplanted human NPCs and effect on behavioural recovery after stroke. (A) Human NPCs (human nuclear antigen+ cells; red) exhibit good survival and migration towards the lesion at 5 weeks post-transplantation. Representative photomicrograph of human NPCs in the peri-infarct region. Grey-shaded area indicates the lesion. (B) Differentiation profile of the human NPCs at 5 weeks post-transplant. (C) Confocal images of differentiation markers co-localizing with human nuclear antigen in the peri-infarct area. (D) Human NPC-grafted animals have significantly improved functional recovery compared with vehicle-injected controls in three out of four behaviour tests; *P < 0.05, **P < 0.01. n = 12 per group, except cylinder test n = 6. Scale bars: A = 50 µm, C = 10 µm. GFAP = glial fibrillary acidic protein; HuNu = human nuclear antigen; TuJ1 = neuronal class III β-Tubulin; Tx = transplantation.
Figure 1 Differentiation fate of transplanted human NPCs and effect on behavioural recovery after stroke. (A) Human NPCs (human nuclear antigen+ cells; red) exhibit good survival and migration towards the lesion at 5 weeks post-transplantation. Representative photomicrograph of human NPCs in the peri-infarct region. Grey-shaded area indicates the lesion. (B) Differentiation profile of the human NPCs at 5 weeks post-transplant. (C) Confocal images of differentiation markers co-localizing with human nuclear antigen in the peri-infarct area. (D) Human NPC-grafted animals have significantly improved functional recovery compared with vehicle-injected controls in three out of four behaviour tests; *P < 0.05, **P < 0.01. n = 12 per group, except cylinder test n = 6. Scale bars: A = 50 µm, C = 10 µm. GFAP = glial fibrillary acidic protein; HuNu = human nuclear antigen; TuJ1 = neuronal class III β-Tubulin; Tx = transplantation.CC BY-NC · PubMed Central
Figure 2 Human NPC transplantation enhances dendritic plasticity after stroke. (A and B) Human NPCs enhance dendritic length (A) and branching (B) at 2 weeks post-transplantation in both the ipsi- and contralesional cortex compared with vehicle-treated animals (n = 4–5 per group). These effects are sustained to 4 weeks post-stroke (n = 5 per group) only in the ipsilesional hemisphere. (C) Representative image of a golgi-stained layer V neuron. (D) Schematic illustrating how branch order is counted for apical and basilar dendrites. (E and F) At 4 weeks post-transplantation human NPCs enhance branching in the middle order branches in ipsilesional layer V neurons. This is more significant in basilar branches (E) compared with apical branches (F). *P < 0.05; **P < 0.01; ***P < 0.001; #P = 0.05.
Figure 2 Human NPC transplantation enhances dendritic plasticity after stroke. (A and B) Human NPCs enhance dendritic length (A) and branching (B) at 2 weeks post-transplantation in both the ipsi- and contralesional cortex compared with vehicle-treated animals (n = 4–5 per group). These effects are sustained to 4 weeks post-stroke (n = 5 per group) only in the ipsilesional hemisphere. (C) Representative image of a golgi-stained layer V neuron. (D) Schematic illustrating how branch order is counted for apical and basilar dendrites. (E and F) At 4 weeks post-transplantation human NPCs enhance branching in the middle order branches in ipsilesional layer V neurons. This is more significant in basilar branches (E) compared with apical branches (F). *P < 0.05; **P < 0.01; ***P < 0.001; #P = 0.05.CC BY-NC · PubMed Central
Figure 3 Human NPCs enhance axonal sprouting post-stroke. (A) Representative confocal images of biotinylated dextran amine (BDA) staining in the contra- and ipsilateral corpus callosum of human NPC- and vehicle-treated animals at 5 weeks post-transplantation. Scale bar = 100 µm. (B) Human NPC-grafted rats have significantly increased BDA-labelled fibre density at 3 weeks (n = 6) and 5 weeks (n = 12) post-transplantation in the cortex, corpus callosum and the ipsilesional striatum. At 5 weeks post-transplantation human NPC-grafted rats also have increased BDA signal in (C) the ipsi- and contralesional thalamus and (D) corticospinal fibres in the contralesional internal capsule and both the contra- and ipsilesional dorsal funiculus in the cervical spinal cord, C5 level. *P < 0.05 human NPC compared with vehicle at same time point. Red oval = BDA injection site; black oval = human NPC transplant site.
Figure 3 Human NPCs enhance axonal sprouting post-stroke. (A) Representative confocal images of biotinylated dextran amine (BDA) staining in the contra- and ipsilateral corpus callosum of human NPC- and vehicle-treated animals at 5 weeks post-transplantation. Scale bar = 100 µm. (B) Human NPC-grafted rats have significantly increased BDA-labelled fibre density at 3 weeks (n = 6) and 5 weeks (n = 12) post-transplantation in the cortex, corpus callosum and the ipsilesional striatum. At 5 weeks post-transplantation human NPC-grafted rats also have increased BDA signal in (C) the ipsi- and contralesional thalamus and (D) corticospinal fibres in the contralesional internal capsule and both the contra- and ipsilesional dorsal funiculus in the cervical spinal cord, C5 level. *P < 0.05 human NPC compared with vehicle at same time point. Red oval = BDA injection site; black oval = human NPC transplant site.CC BY-NC · PubMed Central
Figure 4 Identification of secreted factors mediating neurite plasticity in vitro. (A) Representative images of cortical neurons stained for microtubule-associated protein 2 (MAP2, labels dendrites) and SMI312 (labels axons) co-cultured without (vehicle) and with human NPCs. Scale = 50 µm. (B–D) Human NPCs significantly promoted dendritic branching (B), total dendritic length (C) and axonal outgrowth (D) of the cortical neurons; *P < 0.05 ‘control human NPC’ compared with ‘control vehicle’. Neutralization of the secreted factors with antibodies or the soluble slit receptor Roundabout-Fc significantly reduced the effects of human NPCs on these parameters as indicated. *P < 0.05, **P < 0.01 compared with ‘control human NPC’; #P < 0.05 compared with ‘control vehicle’. TSP = thrombospondins.
Figure 4 Identification of secreted factors mediating neurite plasticity in vitro. (A) Representative images of cortical neurons stained for microtubule-associated protein 2 (MAP2, labels dendrites) and SMI312 (labels axons) co-cultured without (vehicle) and with human NPCs. Scale = 50 µm. (B–D) Human NPCs significantly promoted dendritic branching (B), total dendritic length (C) and axonal outgrowth (D) of the cortical neurons; *P < 0.05 ‘control human NPC’ compared with ‘control vehicle’. Neutralization of the secreted factors with antibodies or the soluble slit receptor Roundabout-Fc significantly reduced the effects of human NPCs on these parameters as indicated. *P < 0.05, **P < 0.01 compared with ‘control human NPC’; #P < 0.05 compared with ‘control vehicle’. TSP = thrombospondins.CC BY-NC · PubMed Central
Figure 5 Effects of human NPCs on anterograde axonal transport in vivo and in vitro. (A) Representative confocal images of amyloid precursor protein (APP) and SMI312 staining of the corpus callosum at 6 weeks post-stroke (5 weeks post-transplant) in uninjured (naïve), vehicle treated (dMCAo, vehicle) and human NPC-grafted (dMCAo, hNPC) animals. Scale = 20 µm (B) Quantification of the percentage of amyloid precursor protein-positive SMI312 puncta to determine the percentage of amyloid precursor protein-positive axons; 3 weeks, n = 6; 5 weeks n = 12. (C) Quantification of total axonal density at 6 weeks post-stroke (n = 12). (D) Schematic of microfluidic assay system for analysis of axonal transport in vitro. (E) Time-lapse confocal images of dextran-labelled vesicles used to measure the rate of axonal transport. Arrowhead indicates the same vesicle at different times. Scale = 5 µm. (F) Human NPCs enhance the rate of axonal transport in cortical neurons compared with vehicle treatment. Neutralization of VEGF, but not other factors significantly reduced this human NPC-mediated effect. *P < 0.05, **P < 0.01. dMCAo = distal middle cerebral artery occlusion.
Figure 5 Effects of human NPCs on anterograde axonal transport in vivo and in vitro. (A) Representative confocal images of amyloid precursor protein (APP) and SMI312 staining of the corpus callosum at 6 weeks post-stroke (5 weeks post-transplant) in uninjured (naïve), vehicle treated (dMCAo, vehicle) and human NPC-grafted (dMCAo, hNPC) animals. Scale = 20 µm (B) Quantification of the percentage of amyloid precursor protein-positive SMI312 puncta to determine the percentage of amyloid precursor protein-positive axons; 3 weeks, n = 6; 5 weeks n = 12. (C) Quantification of total axonal density at 6 weeks post-stroke (n = 12). (D) Schematic of microfluidic assay system for analysis of axonal transport in vitro. (E) Time-lapse confocal images of dextran-labelled vesicles used to measure the rate of axonal transport. Arrowhead indicates the same vesicle at different times. Scale = 5 µm. (F) Human NPCs enhance the rate of axonal transport in cortical neurons compared with vehicle treatment. Neutralization of VEGF, but not other factors significantly reduced this human NPC-mediated effect. *P < 0.05, **P < 0.01. dMCAo = distal middle cerebral artery occlusion.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 71 references

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Andres, R. H., Horie, N., Slikker, W., Keren-Gill, H., Zhan, K., Sun, G., Manley, N. C., Pereira, M. P., Sheikh, L. A., McMillan, E. L., Schaar, B. T., Svendsen, C. N., Bliss, T. M., & Steinberg, G. K.
Affiliations
  • Stanford Medicine (US)
  • Stanford University (US)
  • University of Wisconsin–Madison (US)
  • Cedars-Sinai Medical Center (US)
Corresponding author
  • Bliss, Tonya M.
  • Steinberg, Gary K.
ORCID
Venue
Brain
Publisher
Oxford University Press (OUP)
Published
2011-05-24
Volume
134
Issue
6
Pages
1777-1789
ISSN
  • 0006-8950 (ISSN-L)
  • 1460-2156
DOI
10.1093/brain/awr094
PMC
PMC3102243
OpenAlex
W2009703235
Cited by
329
References
71
Citations by year
2026: 4 · 2025: 9 · 2024: 18 · 2023: 18 · 2022: 14 · 2021: 22 · 2020: 20 · 2019: 16 · 2018: 23 · 2017: 30 · 2016: 18 · 2015: 39 · 2014: 28 · 2013: 33 · 2012: 24
FWCI
10.19
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • Brain (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Bern Open Repository and Information System (University of Bern) (submittedVersion, other-oa)
  • Open Access CRIS of the University of Bern
Funders
  • National Science Foundation
  • Hearst Foundations
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (123221, 117034, PASMP3-123221/1)
  • National Institutes of Health
  • National Institute of Neurological Disorders and Stroke (R01 NS27292, R01NS058784, P01 NS 37520, P01NS057778, P01NS037520, R01NS027292)
Topics
  • Life Sciences › Neuroscience › Developmental Neuroscience › Neurogenesis and neuroplasticity mechanisms
  • Health Sciences › Medicine › Rehabilitation › Stroke Rehabilitation and Recovery
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
Keywords
neural stem cell transplantation, neural progenitor cells, stroke, cerebral ischemia, structural plasticity, dendritic sprouting, axonal transport, corticospinal axons, functional recovery, vascular endothelial growth factor, thrombospondin, slits, co-culture, brain repair
MeSH terms
Analysis of Variance, Animals, Axonal Transport, Biotin, Cell Survival, Cells, Cultured, Cerebral Cortex, Brain Ischemia, Corpus Callosum, Dendrites, Dextrans, Disease Models, Animal, Fetus, Gene Expression Regulation, Humans, Male, Nerve Tissue Proteins, Neuronal Plasticity, Psychomotor Performance, Rats, Nude, RNA, Messenger, Time Factors, Vibrissae, Rats, Sprague-Dawley, Brain Infarction, Rats, Neural Stem Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review